Acuta Capital Partners, LLC Veracyte, Inc. Transaction History

Acuta Capital Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$20.78 - $29.99 $2.34 Million - $3.37 Million	-112,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$23.87 - $30.93 $8.81 Million - $11.4 Million	-369,000 Reduced 76.64%	112,500 $2.7 Million
Q2 2019 Aug 14, 2019	BUY	$22.1 - $28.56 $2.21 Million - $2.86 Million	100,000 Added 26.21%	481,500 $13.7 Million
Q1 2019 May 14, 2019	SELL	$12.0 - $25.76 $732,000 - $1.57 Million	-61,000 Reduced 13.79%	381,500 $9.55 Million
Q4 2018 Feb 14, 2019	SELL	$9.15 - $14.85 $5.95 Million - $9.65 Million	-650,000 Reduced 59.5%	442,500 $5.57 Million
Q3 2018 Nov 07, 2018	SELL	$9.55 - $12.64 $15 Million - $19.8 Million	-1,567,710 Reduced 58.93%	1,092,500 $10.4 Million
Q2 2018 Aug 15, 2018	SELL	$5.39 - $9.66 $3.55 Million - $6.35 Million	-657,790 Reduced 19.82%	2,660,210 $24.8 Million
Q1 2018 May 15, 2018	BUY	$5.44 - $6.97 $124,516 - $159,536	22,889 Added 0.69%	3,318,000 $18.4 Million
Q3 2017 Nov 14, 2017	BUY	$7.81 - $8.77 $25.7 Million - $28.9 Million	3,295,111	3,295,111 $28.9 Million

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.